MedTrace Logo

T2D Intermittent Nonprescription Sensors for Informed Glucose Health Tracking

NCT07422831 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2026-04-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if periodic use of over-the-counter continuous glucose monitoring (CGM) can support glucose management in people with type 2 diabetes not using insulin being treated in primary care settings. The main questions it aims to answer are:

* Is periodic use of CGM every 30 or 90 days for six months associated with reduced A1C compared to usual care at baseline?
* Is periodic use of CGM every 30 or 90 days for six months associated with increased time in range and time in tight range compared to usual care at baseline?
* Is periodic use of CGM every 90 days over six months associated with non-inferior A1C reduction compared to periodic use of CGM every 30 days?
* Are clinician feasibility and acceptability of periodic, OTC CGM higher than for prescription CGM?
* How acceptable is periodic, OTC CGM to people with non-insulin-treated type 2 diabetes? Researchers will compare use of periodic CGM every 30 and 90 days to see if less frequent periodic CGM use can support glucose management as effectively as more frequent use.

Participants will:

* be assigned to one of two groups using the 15-day Dexcom Stelo® glucose biosensor every 30 or 90 days over a six-month period.
* receive Stelo devices every 30 or 90 days (as randomized)
* complete up to 9 virtual or in-person visits with the study team.
* complete 3 fingerstick A1c tests.
* wear a blinded CGM device at 3 time points outside of Dexcom Stelo® use.
* complete a survey at the end of the study.

Conditions

Interventions

DEVICE

Periodic, over-the-counter continuous glucose monitoring

Periodic, over-the-counter continuous glucose monitoring for people with non-insulin-treated type 2 diabetes treated in primary care settings.

Sponsors & Collaborators

Principal Investigators

  • Tamara Oser, MD · University of Colorado Denver Anschutz Medical Campus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-02
Primary Completion
2027-12-31
Completion
2028-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07422831 on ClinicalTrials.gov